Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
about
Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugsProstate cancer relevant antigens and enzymes for targeted drug deliveryThe novel fusion proteins, GnRH-p53 and GnRHIII-p53, expression and their anti-tumor effectSynthesis, characterization and stability of a luteinizing hormone-releasing hormone (LHRH)-functionalized poly(amidoamine) dendrimer conjugate.Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomesReceptor-targeting phthalocyanine photosensitizer for improving antitumor photocytotoxicity.Gonadotropin-releasing hormone receptor activates GTPase RhoA and inhibits cell invasion in the breast cancer cell line MDA-MB-231CGB and GNRH1 expression analysis as a method of tumor cells metastatic spread detection in patients with gynecological malignances.Phthalocyanine-loaded graphene nanoplatform for imaging-guided combinatorial phototherapy.Antitumor effects of cecropin B-LHRH' on drug-resistant ovarian and endometrial cancer cells.A biomimetic approach for enhancing the in vivo half-life of peptides.Synthesis and biological evaluation of a novel pentagastrin-toxin conjugate designed for a targeted prodrug mono-therapy of cancer.In vivo effect of an luteinizing hormone-releasing hormone analog on vascular endothelial growth factor and epidermal growth factor receptor expression in mammary tumorsLHRH-targeted nanogels as a delivery system for cisplatin to ovarian cancer.A conjugate of methotrexate and an analog of luteinizing hormone releasing hormone shows increased efficacy against prostate cancerPotentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonistsReceptor-mediated tumor targeting based on peptide hormones.Possibilities to increase the effectiveness of doxorubicin in cancer cells killing.Emerging drugs for endometrial cancer.GnRH and GnRH receptors in the pathophysiology of the human female reproductive system.Synthesis, characterization and systematic comparison of FITC-labelled GnRH-I, -II and -III analogues on various tumour cells.Multifunctional platinum-based nanoparticles for biomedical applications.Gonadotropin‑releasing hormone inhibits the proliferation and motility of nasopharyngeal carcinoma cells.Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting.Stability, permeability and growth-inhibitory properties of gonadotropin-releasing hormone liposaccharides.An efficient chemical approach to bispecific antibodies and antibodies of high valencyA study on liposomal encapsulation of a lipophilic prodrug of LHRH.New therapies for advanced, recurrent, and metastatic endometrial cancers.Characterization of luteinizing hormone-releasing hormone receptor type I (LH-RH-I) as a potential molecular target in OCM-1 and OCM-3 human uveal melanoma cell lines.Modification of daunorubicin-GnRH-III bioconjugates with oligoethylene glycol derivatives to improve solubility and bioavailability for targeted cancer chemotherapy.Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery.Large set data mining reveals overexpressed GPCRs in prostate and breast cancer: potential for active targeting with engineered anti-cancer nanomedicines.
P2860
Q26849241-6899D53B-3367-4A07-ACB8-0F77241485D6Q27013843-FB26E377-DF70-45F9-BFDD-CEC27522CA3BQ28534798-D8571FC5-DC74-4679-BB74-9F3F94EC05B5Q33313432-51089407-DA17-447C-808F-172821F0AA13Q34101055-56A7835E-3E3D-40A3-A4A2-C54684E3975FQ34170191-96E9C9A9-3713-404A-AFB1-F39E1927DB21Q34302297-3A1F9014-B4BD-484D-A905-BF17BEC7C89EQ34486740-EBC9B8C9-1ACE-4F98-B3A0-775E3BBC5BCEQ35213724-A6F80D8C-02D3-4B5C-B8F5-266DB316F82DQ35229094-2754E81E-A07D-4F59-AF18-88DEB13148A3Q35972278-5B58F170-C3B0-4C67-A343-EE8241649610Q36073308-9B26D850-6B62-4CF9-8B57-108C90B58223Q37083440-EE03F7B3-FCF2-40E7-8FDA-24A5C695111BQ37235589-004D398B-9D4F-4675-A642-75766AB1307DQ37259176-926E71EC-E37E-4E73-9D14-230E91284396Q37274382-7D917BC2-CA2C-4AD8-A13E-9524DABEB428Q37495105-E4983FB9-DB9D-4EE6-8B89-A12340560257Q37641368-6A065788-CCED-43D7-A145-ACE3139E817CQ37937579-19ACC510-0774-40FF-AFC7-09786BB87326Q38261469-3392E73F-085A-4298-8CB6-B9095BC3F51DQ38682630-5B3FA85F-8A9A-4307-85EC-EC8D14296831Q38756598-2EFD396A-245F-43A9-9C15-B604B1F507F9Q38812240-B4927E76-0980-46DA-9332-7B5B6594C5B2Q38855783-AD621139-8748-4211-93AC-82651BA00C9FQ38882916-1B05CAE1-8D08-46B0-9F76-8F004994C2F0Q38939445-AE3FEDBC-B93B-46ED-ABE5-D2831B0754C3Q39842559-9DDBDC9E-BDE7-4C1F-8B12-78A0A1902670Q40970844-FAB86208-0DCF-4AC1-8E32-70736255E780Q47103210-246EDB6A-F0BB-4F9F-8834-4AE216CAA230Q50350314-3F16357D-C8E3-47C6-A69A-32F72B0AF02CQ53589895-C5A54865-3664-436E-972A-37EA7B5B8625Q55082165-D76C889F-655F-4021-A989-0A5AB24048ACQ55286689-B6898092-F124-4A21-8825-8413CF15F7F5
P2860
Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Targeting of cytotoxic luteini ...... metrial, and prostate cancers.
@ast
Targeting of cytotoxic luteini ...... metrial, and prostate cancers.
@en
type
label
Targeting of cytotoxic luteini ...... metrial, and prostate cancers.
@ast
Targeting of cytotoxic luteini ...... metrial, and prostate cancers.
@en
prefLabel
Targeting of cytotoxic luteini ...... metrial, and prostate cancers.
@ast
Targeting of cytotoxic luteini ...... metrial, and prostate cancers.
@en
P2860
P1476
Targeting of cytotoxic luteini ...... metrial, and prostate cancers.
@en
P2093
Attila Nagy
P2860
P304
P356
10.1095/BIOLREPROD.105.043489
P407
P577
2005-07-20T00:00:00Z